Lyell Immunopharma, Inc. LYEL

About Lyell Immunopharma, Inc. (LYEL): stock profile, AI score and financials

Lyell Immunopharma, Inc. (LYEL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LYEL at 9.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,878 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (2.1) and revenue growth (2.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Lyell Immunopharma, Inc. reports quarterly revenue of $4.0K, net income of $-44.8M, free cash flow of $-34.2M. Top institutional holders of LYEL by reported 13-F value include ARCH Venture Management, GSK plc, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. LYEL trades on the Nasdaq exchange and files with the SEC under CIK 1806952. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LYEL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lyell Immunopharma, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1806952 →